Abstract
Colorectal cancer is one of the most intensively studied cancer types, partly because of its high prevalence but also because of the existence of precursor lesions, known as adenomas, which can be detected endoscopically and removed. Theoretically, removal of these adenomas would prevent most cases of colorectal cancer from developing. Characteristic morphological steps in the evolution of these precursor lesions have been elucidated at a molecular level and the adenoma–carcinoma sequence, as this has become known, is one of the classical examples of stepwise progression of cancer. Gaining this knowledge has been facilitated by the occurrence of a variety of forms of familial intestinal cancer, the molecular genetic background of which has been largely clarified. Apart from early detection of familial forms of colorectal cancer and its use in genetic counseling, until recently this knowledge has had little impact on the clinical management of colorectal cancer. Classical clinicopathological parameters remain the essential parameters determining how a colorectal patient will be treated. This has dramatically changed in the last five years. With drugs specifically targeting the EGF receptor having been shown effective in colorectal cancer, mechanisms responsible for resistance have been explored. The finding that KRAS-mutated cancers do not respond to anti-EGFR treatment has had a profound impact on clinical management and on molecular diagnostics of colorectal cancer. With new targeted drugs in the pipeline it is highly likely that companion diagnostics will go through a period of explosive development. In this chapter we will discuss the biology of intestinal mucosa and its disturbance in cancer. We will review cancer family syndromes and the impact of understanding these on a molecular level has had on our understanding of colorectal cancer. Finally we will review how molecular diagnostics now contribute to the clinical management of colorectal cancer and what can be expected in this field in the near future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Readings
Bohanes P, LaBonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011;38:576–87.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–87.
Bosch LJ, Carvalho B, Fijneman RJ, et al. Molecular tests for colorectal cancer screening. Clin Colorectal Cancer. 2011;10:8–23.
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010.
van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241–60.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.
Gala M, Chung DC. Hereditary colon cancer syndromes. Semin Oncol. 2011;38:490–9.
Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011;10:73–80.
Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–70.
Liang JJ, Alrawi S, Tan D. Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma. Int J Clin Exp Pathol. 2008;1:317–24.
Migliore L, Migheli F, Spisni R, Coppede F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362.
Merlos–Suárez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell. 2011;8:511–24.
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in Stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol. 2009;28:466–74.
Sato T, van Es JH, Snippert HJ, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2011;469:415–8.
Scoville DH, Sato T, He XC, Li L. Current view: intestinal stem cells and signaling. Gastroenterology. 2008;134:849–64.
Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10.
Vries RG, Huch M, Clevers H. Stem cells and cancer of the stomach and intestine. Mol Oncol. 2010;4:373–84.
Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378–89.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bosman, F.T. (2013). Molecular Pathology of Colorectal Cancer. In: Cheng, L., Eble, J. (eds) Molecular Surgical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4900-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4900-3_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4899-0
Online ISBN: 978-1-4614-4900-3
eBook Packages: MedicineMedicine (R0)